The US has approved its first treatment for peanut allergies in children.
美國(guó)首次批準(zhǔn)治療兒童花生過敏。

The drug AR101, or Palforzia, uses oral immunotherapy, with children given tiny but increasing amounts of peanut protein over a six-month period under medical supervision.
這個(gè)藥物叫作AR101，或Palforzia，采用口服免疫療法，六個(gè)月的醫(yī)學(xué)觀察期內(nèi)可以給兒童少量花生蛋白，并逐漸加量。

After that, users must continue to take a daily dose to be able to tolerate accidental exposure.
然后，服藥者必須每天堅(jiān)持吃點(diǎn)，以便在意外接觸花生時(shí)能挺住。

The treatment is not a cure and makers warn that the risk of a potentially fatal anaphylactic reaction remains.
這一療法不能根治，制藥商警告說依然存在潛在致命過敏反應(yīng)。

And patients must continue to avoid peanuts in their diet.
病人飲食依舊不能含有花生。

Peanuts are the most common food allergen in the US, with an increase in the number of those affected by food allergies across the West in recent decades.
花生是美國(guó)最常見的食物過敏原，近些年在西方受食物過敏影響人數(shù)有所上升。

While trials to desensitise patients with peanut allergies have previously taken place in the US and elsewhere, the drug is the first to be approved by the US Food and Drug Administration (FDA). The drug has not yet been authorised for use in the UK.
雖然此前美國(guó)和其他地區(qū)進(jìn)行過花生過敏患者的脫敏試驗(yàn)，但這是首個(gè)經(jīng)美國(guó)食品藥品監(jiān)督管理局批準(zhǔn)的藥品，但在英國(guó)尚未獲準(zhǔn)使用。

Palforzia, which has been approved for use in patients aged between four and 17, comes in the form of a powder which is sprinkled on food.
Palforzia藥物獲準(zhǔn)用于4至17歲患者的治療，以粉末形式灑在食物上。

Last year, scientists at King's College London said that oral immunotherapy offered "protection but not a cure" for peanut allergies, with treatment only effective while patients continued taking small amounts of the allergen.
去年倫敦國(guó)王學(xué)院的科學(xué)家說口服免疫療法對(duì)于花生過敏者只能“起到保護(hù)作用，卻不能根治”，而且患者要一直吃少量過敏原食物這種療法才有效。

?

翻譯：菲菲